| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | vigabatrin (Kigabeq®) |
| Formulation | 100 mg and 500 mg soluble tablet |
| Reference number | 3946 |
| Indication | Treatment of infantile spasms (West's syndrome) and resistant partial epilepsy (focal onset seizures) in infants and children |
| Company | ORPHELIA Pharma SAS |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 07/11/2018 |